Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0486

Next Previous
Drug Profile

AZD 0486

Alternative Names: AZD-0486; CD19 x CD3 T-BsAb - TeneoBio; TNB-486

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TeneoTwo
  • Developer AstraZeneca; TeneoBio; TeneoTwo
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Follicular lymphoma
  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Jan 2025 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in Australia, USA, Japan, South Korea, United Kingdom (SC) (NCT06564038)
  • 30 Jan 2025 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Monotherapy, Second-line therapy or greater) in USA, Australia, Japan, South Korea, United Kingdom (SC) (NCT06564038)
  • 30 Jan 2025 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, Australia, Japan, South Korea, United Kingdom (IV) (NCT06564038)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top